Michael Houghton Acquires 3,202 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now directly owns 3,202 shares of the company’s stock, valued at $49,983.22. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Assembly Biosciences Stock Down 1.6 %

Shares of NASDAQ:ASMB opened at $15.78 on Thursday. The business has a fifty day simple moving average of $16.01 and a 200-day simple moving average of $15.60. Assembly Biosciences, Inc. has a 52 week low of $9.12 and a 52 week high of $19.93.

Analyst Upgrades and Downgrades

ASMB has been the subject of several analyst reports. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th. Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $35.00 in a research report on Friday, September 20th.

Institutional Trading of Assembly Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares during the period. Acadian Asset Management LLC raised its stake in Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares during the period. FMR LLC raised its position in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Assembly Biosciences during the second quarter valued at approximately $6,421,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.